Many investors and analysts have increasingly lowered their expectations for the U.S. and China to find a quick resolution.World Economyread more
Billionaire investor Howard Marks, the co-chairman of Oaktree Capital, predicts there won't be a recession in the U.S. for another two years.US Economyread more
Network officials also said voters should expect more of a Koch focus on grassroots activism throughout the 2020 election cycle.Politicsread more
One person was killed and five others wounded on Thursday in a shooting on the streets of Washington, D.C., not far from the White House, police said.U.S. Newsread more
Stores are extending hours and cities are spending on light shows as China tries to encourage consumers to spend more money at night.China Economyread more
New research suggests fewer girls pursue careers in STEM — science, technology, engineering and math — because they're better than boys at reading.Closing The Gapread more
Stocks in Asia Pacific edged up in Friday afternoon trade as a series of developments overnight on the U.S.-China trade front dampened hopes of a deal being reached between...Asia Marketsread more
GM's usage of temporary workers, potential closure of plants and health care contributions remain major sticking points, according to people familiar with the talks.Autosread more
In a room full of avowed capitalists, policies that sound to some like socialism are bound not to go over well.Delivering Alpharead more
Trump has criticized Facebook numerous times since becoming president, most recently posting on Twitter that the company's proposed digital currency, libra, will "have little...Technologyread more
Republicans and Democrats have long since separated themselves by ideology, leaving each more uniformly conservative or liberal than ever. And now a new data analysis by the...Politicsread more
Shares of biotech company Achillion Pharmaceuticals were more than 20 percent lower Monday in premarket trading after it announced its hepatitis C collaboration with a Johnson & Johnson pharmaceutical unit ended.
Johnson & Johnson was down slightly in premarket trading after its Janssen Sciences Ireland said it would discontinue further development of the investigational hepatitis C treatment regimen JNJ-4178 amid a crowded market.
Janssen said there is an increasing availability of a number of highly effective therapies addressing the medical need. Hepatitis C is a contagious liver disease which affects about 3.2 million Americans, according to the Centers for Disease Control and Prevention.
In a statement Monday, Achillion President and CEO Milind Deshpande said he was "disappointed" by the Janssen decision, given the positive data presented in a recent study.
Ongoing phase two studies with JNJ-4178 will be completed as planned, Janssen said in a statement, but will cease thereafter.
"Going forward, our hepatitis R&D efforts will focus on chronic hepatitis B, where a high unmet medical need still exists," Lawrence Blatt, global therapeutic area head, infectious disease therapeutics, Janssen, said in a statement.